Study guide
16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
Philippine Medical Technologists Licensure Examination MTLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety
1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards
2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function
2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice
3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology
3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology
4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety
4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria
5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology
6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology
6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods
7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control
8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders
8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry
9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders
9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests
10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing
10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures
11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
12 Chapter 12: Clinical Serology and Immunology
12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)
13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology
13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control
14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens
14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens
15 Chapter 15: Histopathologic Techniques and Cytotechnology
15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records
16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics
16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
Key Takeaways Explain This Topic AI
DOH Administrative Order No. 2021-0037, implementing RA 4688, classifies general clinical laboratories by service capability as primary, secondary, tertiary, or limited-service, each requiring a DOH License to Operate.
Republic Act No. 7719 phased out commercial blood banks and promotes voluntary non-remunerated blood donation; Philippine blood services screen every donated unit for HIV, HBV, HCV, syphilis, and malaria.
Under Republic Act No. 9165, a positive drug screen must be confirmed by a chromatographic-mass spectrometric test, and a drug test certificate is valid for one year from issuance.
Under Republic Act No. 9288, heel-prick newborn screening is done after 24 hours of life but no later than 3 days, and the expanded panel now covers 29 conditions.
The practice of medical technology is guided by the four pillars of bioethics—Autonomy, Beneficence, Non-maleficence, and Justice—alongside the PAMET Code of Ethics, mandating immediate verbal critical value reporting and uncompromised patient confidentiality.
Last updated: October 2026
Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
Beyond Republic Act No. 5527, professional medical technology practice in the Philippines intersects with healthcare statutes enacted to safeguard clinical laboratory standards, ensure transfusion safety, enforce substance abuse surveillance, screen newborns, protect patient privacy, and govern human immunodeficiency virus (HIV) diagnostics. In parallel, the Medical Technologist's Code of Ethics and foundational bioethical principles provide the moral framework for laboratory decision-making.
- 1. Related Philippine Healthcare and Laboratory Statutes ┌──────────────────────────────────────────────┐
- │ Key Philippine Healthcare & Lab Statutes │
- └──────────────────────┬───────────────────────┘
- │
- ┌───────────────────┬───────────────┴───────────────┬───────────────────┐
- ▼ ▼ ▼ ▼
- ┌──────────────┐ ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
- │ RA 4688 │ │ RA 7719 │ │ RA 9165 │ │ RA 9288 │
- │Clinical Labs │ │Blood Services│ │Dangerous Drug│ │ Newborn │
- │ Licensing │ │ (Voluntary) │ │Screen/Confirm│ │ Screening │
- └──────┬───────┘ └──────┬───────┘ └──────┬───────┘ └──────┬───────┘
- │ │ │ │
- DOH AO 2021-0037 • Phase-out of • Screening: • 24 hrs to 3 days
- Primary commercial banks Immunoassay • Heel-prick filter
- Secondary • Screen 5 TTIs: • Confirm: paper (Whatman)
- Tertiary HIV, HBV, HCV, GC-MS, LC-MS • ENBS panel: 29
- Limited service Syphilis, Malaria • Custody: 60 mL disorders (CH, CAH,
- 32.5°C-37.7°C G6PD, PKU, MSUD)
- 1. Republic Act No. 4688: The Clinical Laboratory Law of 1966
Regulatory Body : Administered by the Department of Health (DOH) through the Health Facilities and Services Regulatory Bureau (HFSRB) and the regional Centers for Health Development, which issue the DOH License to Operate (LTO) . A DOH Permit to Construct is required before building, renovating, expanding, changing ownership of, or relocating a laboratory.
Administrative Order No. 2021-0037 (11 June 2021): "New Rules and Regulations Governing the Regulation of Clinical Laboratories in the Philippines." It replaced AO 2007-0027 and links laboratory licensing to the primary care facility rules issued under the Universal Health Care Act.
Classification by Ownership : Government (national government, local government unit, or other public agency) vs. Private (individual, corporation, association, or organization).
Classification by Institutional Character : Institution-based (located within, and operating as part of, a DOH-licensed health facility) vs. non-institution-based (operating independently). The older AO 2007-0027 used the terms hospital-based and non-hospital-based.
Classification by Function : Clinical pathology, anatomic pathology, and molecular pathology.
Classification by Service Capability (general clinical laboratory):
Category Minimum Service Capabilities under AO 2021-0037
Primary Urinalysis, fecalysis, fecal occult blood, rapid pregnancy test, and wet smear for Trichomonas ; FBS/RBS, OGTT, lipid profile, creatinine, BUN, and uric acid; CBC with differential and quantitative platelet count; forward and reverse ABO grouping with Rh(D) typing by tube method; rapid tests for dengue, syphilis, hepatitis B, and HIV screening; TB smear microscopy (DSSM) or nucleic acid amplification for government facilities
Secondary All primary services plus serum electrolytes (Na, K, Cl), ALT, and AST; PT and aPTT for hospital-based laboratories; Gram stain and KOH mount; Pap smear
Tertiary All secondary services plus other clinical chemistry (arterial blood gases for hospital-based laboratories), machine-based serology and immunology (such as tumor markers, thyroid function tests, and hepatitis profile), aerobic and anaerobic culture and sensitivity, and cytology and histopathology for hospital-based laboratories
Limited service One or two specialized tests outside anatomic and molecular pathology, such as hormones, trace metals, tumor markers, or allergy panels; this category also covers DOH program tests such as Kato-Katz, malarial smear, filarial smear, slit-skin smear, and RPR
Head of the Laboratory : A pathologist certified in clinical pathology by the Philippine Board of Pathology. A tertiary laboratory that offers anatomic pathology must be headed by a pathologist certified in both anatomic and clinical pathology. Limited exceptions exist for geographically isolated and disadvantaged areas (GIDAs).
Older figures to recognize : Many reviewers still quote minimum floor areas of 10, 20, and 60 m² for primary, secondary, and tertiary laboratories, and place crossmatching in the secondary category. Those details come from the superseded AO 2007-0027. AO 2021-0037 instead sets space standards by function (for example, 6 m² per blood extraction chair).
2. Republic Act No. 7719: National Blood Services Act of 1994
Primary Mandate : Promotes voluntary non-remunerated blood donation , prohibits the commercialization of blood, and phased out commercial blood banks in the Philippines to secure a safe blood supply. It replaced the Blood Bank Act of 1956 (RA 1517).
Mandatory TTI Screening : Under the National Voluntary Blood Services Program, every donated unit is screened for five transfusion-transmissible infections (TTIs) :
- Human Immunodeficiency Virus (HIV-1 and HIV-2);
- Hepatitis B Virus (HBsAg);
- Hepatitis C Virus (Anti-HCV);
- Syphilis ( Treponema pallidum serology);
Malaria parasites ( Plasmodium blood smear or antigen detection).
3. Republic Act No. 9165: Comprehensive Dangerous Drugs Act of 2002
Accredited Laboratory Tiers :
Screening Laboratory : Employs rapid immunochromatographic or automated immunoassay methods. Identifies the presumptive presence of drugs or metabolites; routine Philippine panels test for methamphetamine (shabu) and tetrahydrocannabinol (THC, cannabis) metabolites.
Confirmatory Laboratory : Utilizes reference chromatographic-mass spectrometric instrumentation: Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Mass Spectrometry (LC-MS) . Section 36 of RA 9165 requires two methods, a screening test and a confirmatory test, so every positive screen must be confirmed before it is reported as positive.
Chain of Custody (COC) Protocols :
Specimen collection requires the standardized Custody and Control Form (CCF) .
Urine volume collected must measure a minimum of 60 mL .
The collector checks the volume, appearance, and temperature in full view; temperature is read within 4 minutes of voiding, and the acceptable range taught in Philippine drug-testing training is 32.5°C to 37.7°C .
Laboratory validity testing evaluates creatinine, specific gravity, pH, nitrites, and oxidizing adulterants; dilute, substituted, or adulterated specimens are reported as such rather than as negative.
Validity of Drug Test Certificate : Valid for one (1) year from the date of issue.
4. Republic Act No. 9288: Newborn Screening Act of 2004
Mandate : Mandatory screening of all newborns to detect congenital metabolic disorders before irreversible neurological impairment or death occurs.
Timing and Specimen : Capillary blood collected via heel-prick onto a filter-paper collection card (Whatman 903, formerly Schleicher & Schuell 903) after 24 hours of life but not later than 3 days from complete delivery. A newborn who must be placed in intensive care may be exempted from the 3-day rule but must be tested by 7 days of age.
Expanded Newborn Screening (ENBS) : Offered from December 2014, ENBS expanded the panel from 6 to 28 conditions using tandem mass spectrometry (MS/MS) and hemoglobin testing; argininosuccinic aciduria was added in 2018, bringing the panel to 29 conditions . Key conditions include:
Congenital Hypothyroidism (CH) : Elevated TSH; prevents irreversible intellectual disability (cretinism).
Congenital Adrenal Hyperplasia (CAH) : Elevated 17-hydroxyprogesterone (17-OHP); prevents lethal salt-wasting crises.
Galactosemia (GAL) : Elevated total galactose; prevents hepatic cirrhosis, cataracts, and E. coli sepsis.
Phenylketonuria (PKU) : Elevated phenylalanine; prevents severe brain damage.
Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency : Decreased G6PD enzyme activity; prevents severe acute hemolytic anemia and kernicterus.
Maple Syrup Urine Disease (MSUD) : Elevated branched-chain amino acids (leucine, isoleucine, valine); prevents encephalopathy.
Fatty Acid Oxidation Disorders and Organic Acidemias .
5. Other Key Healthcare Statutes
Republic Act No. 10173 (Data Privacy Act of 2012) : Diagnostic results and genetic profiles represent sensitive personal information. Data breaches must be reported to the National Privacy Commission (NPC) within 72 hours .
Republic Act No. 11166 (Philippine HIV and AIDS Policy Act of 2018) : Replaced RA 8504. Lets a person aged 15 to below 18 consent to voluntary, confidential HIV testing without parental or guardian consent; a person below 15 who is pregnant or engaged in high-risk behavior may be tested with the assistance of a licensed social worker or health worker. Forbids compulsory testing as a prerequisite for employment, education, or travel.
Republic Act No. 10912 (Continuing Professional Development Act of 2016) : Requires registered professionals to earn CPD credit units, checked when the PRC Professional Identification Card is renewed every three years. PRC has adjusted the required units by resolution, so check the current requirement before renewal.
Republic Act No. 8981 (PRC Modernization Act of 2000) : Defines the powers of the Professional Regulation Commission and its Professional Regulatory Boards, including the Board of Medical Technology, over licensure examinations, registration, and discipline.
Republic Act No. 11332 (2019) : The Mandatory Reporting of Notifiable Diseases and Health Events of Public Health Concern Act. It requires laboratories and health facilities to report notifiable diseases to the DOH surveillance system.
2. Professional Organizations and Governance
PAMET (Philippine Association of Medical Technologists) :
The sole Accredited Integrated Professional Organization (AIPO) for registered medical technologists in the Philippines.
Organized on September 15, 1963 by Crisanto G. Almario (Father of PAMET) at the Public Health Laboratory on Quiricada Street, Sta. Cruz, Manila.
First President: Charlemagne T. Tamondong , elected at the first national convention on September 20, 1964 at Far Eastern University.
Registered with the Securities and Exchange Commission on October 14, 1969, a few months after RA 5527 was enacted on June 21, 1969.
PASMETH (Philippine Association of Schools of Medical Technology and Public Health) :
The association of schools offering the medical technology program, formed in 1970 .
Works with CHED and PAMET on curriculum, faculty development, and licensure examination performance.
3. Code of Ethics of the Medical Technologist
The Code of Ethics of the Medical Technologist outlines solemn obligations:
Pledge of Dedication : Acknowledge that the practice of medical technology is a noble calling dedicated to safeguarding human health and human life.
Truthful Reporting : Render laboratory reports with absolute veracity, intellectual honesty, and accuracy, never altering or inventing diagnostic findings.
Professional Conduct : Avoid association with fraudulent enterprises, misleading enterprises, or unauthorized diagnostic centers.
Confidentiality : Treat all patient information, test data, and clinical consultations with strict confidentiality, revealing findings only to the attending physician or legal authorities.
Inter-professional Relationships : Cooperate harmoniously with physicians and healthcare workers, offering constructive assistance without encroaching upon the clinical practice of medicine.
4. Bioethics and Laboratory Medicine Principles
Medical technologists frequently confront complex ethical dilemmas governed by the four classical pillars of bioethics: ┌──────────────────────────────────────────────┐
- │ Four Classical Bioethical Pillars │
- └──────────────────────┬───────────────────────┘
- │
- ┌───────────────────┬───────────────┴───────────────┬───────────────────┐
- ▼ ▼ ▼ ▼
- ┌──────────────┐ ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
- │ Autonomy │ │ Beneficence │ │Non-Maleficenc│ │ Justice │
- └──────┬───────┘ └──────┬───────┘ └──────┬───────┘ └──────┬───────┘
- │ │ │ │
- Informed consent • Promote patient • "Primum non • Fair, equitable
- Right to refuse welfare nocere" allocation of
- Confidentiality • Maintain robust • Prevent errors diagnostic tests
- Truth-telling quality assurance • Prevent specimen • Equal access
- (veracity) • Validate tests mislabels without bias
Principle of Autonomy : Respects the patient's intrinsic right to self-determination, informed consent, and personal dignity. The patient has the right to understand diagnostic procedures, receive honest explanations, and refuse phlebotomy or testing.
Principle of Beneficence : The moral obligation to act in the best interest of the patient. In laboratory operations, beneficence requires implementing quality control, verifying questionable results, and promptly reporting critical values to accelerate life-saving therapy.
Principle of Non-Maleficence ( Primum Non Nocere ) : "First, do no harm." Requires active prevention of diagnostic errors, elimination of specimen misidentification, and refusal to report compromised samples (such as severely hemolyzed chemistry specimens) that could trigger inappropriate clinical intervention.
Principle of Justice : Mandates fairness, equity, and impartiality in delivering diagnostic services, ensuring that diagnostic testing is administered without discrimination based on socioeconomic status, religion, gender, or nationality.
Clinical Laboratory Ethical Dilemmas
Critical Values Management (Panic Values) :
A critical value represents an immediate, life-threatening laboratory finding that demands emergency physician intervention (e.g., serum potassium < 2.5 or > 6.5 mmol/L <2.5\text{ or } >6.5\text{ mmol/L} < 2.5 or > 6.5 mmol/L , platelet count < 20 × 10 9 /L <20\times 10^9\text{/L} < 20 × 1 0 9 /L , positive blood culture Gram stain).
Reporting Mandate : The medical technologist must immediately initiate verbal notification to the attending physician or licensed nurse, execute a mandatory "read-back" protocol (confirming that the receiver writes down and reads back the patient name, MRN, test, and numerical value), and document the call date, precise timestamp, caller identity, and receiver identity in the laboratory information system.
Specimen Mislabels and Analytical Errors :
When a specimen mislabeling or analytical error is identified post-release, non-maleficence mandates immediate verbal recall of the incorrect report , followed by an amended written report explaining the correction. Concealing a diagnostic error violates professional ethics and can expose the laboratory to administrative and legal liability.
Confidentiality vs. Public Health Notification :
While medical technologists owe strict confidentiality to patients, this duty is limited when statutory reporting mandates public health action (e.g., coded, confidential reporting of confirmed HIV cases and reporting of tuberculosis and other notifiable diseases to DOH surveillance under RA 11332).